According to Corgnac et al., NSCLC reduces the cell surface of the CD103 integrin ligand E-cadherin, starting an epithelial-to-mesenchymal transition program that enabled CSC to withstand particular CD8+ CD103+ TRM cell-mediated cytotoxicity and maybe also resistance to cancer immunotherapy [91]. The gene discussed is CD8A; the disease is cancer.